473 related articles for article (PubMed ID: 4581414)
21. The rationale and approach to immunosuppressive therapy.
Frenkel EP; Stone MJ
Adv Intern Med; 1971; 17():21-49. PubMed ID: 4122086
[No Abstract] [Full Text] [Related]
22. [Tumor immunology].
Cerni CM
Subsid Med; 1974; 2():21-5. PubMed ID: 4606048
[No Abstract] [Full Text] [Related]
23. [Immunotherapy of malignant tumors].
Adolphs HD
Med Klin; 1975 Feb; 70(7):255-66. PubMed ID: 1091835
[No Abstract] [Full Text] [Related]
24. [The immunotherapeutic approaches to the management of leukemia and neoplasms].
Leu TP
Zhonghua Yi Xue Za Zhi; 1974 May; 5():310-4. PubMed ID: 4211699
[No Abstract] [Full Text] [Related]
25. [Problems of the immunotherapy of malignant neoplasma].
Trapeznikov NN; Iavorskiĭ VV
Klin Med (Mosk); 1975 May; 52(5):15-22. PubMed ID: 1094178
[No Abstract] [Full Text] [Related]
26. Summary of the conference on immunology of carcinogensis.
Baker CG
Natl Cancer Inst Monogr; 1972 Dec; 35():445-60. PubMed ID: 4572835
[No Abstract] [Full Text] [Related]
27. Cancer active immunotherapy. Immunoprophylaxis and immunorestoration. An introduction.
Mathé G
Recent Results Cancer Res; 1976; 55():1-402. PubMed ID: 1087040
[No Abstract] [Full Text] [Related]
28. The gordian knot of tumour immunology.
Amlot P
Guys Hosp Rep; 1974; 123(1):43-51. PubMed ID: 4549511
[No Abstract] [Full Text] [Related]
29. [Stimulation of cellular immunity in patients with malignant tumors].
Govallo VI; Grigor'eva MP; Kosmiadi GA; Vostrikova NA
Vopr Onkol; 1973; 19(12):30-4. PubMed ID: 4544936
[No Abstract] [Full Text] [Related]
30. [Tumor immunology].
Milas L; Silobrcić V
Lijec Vjesn; 1970; 92(1):5-33. PubMed ID: 4932237
[No Abstract] [Full Text] [Related]
31. [Tumor immunology].
Micksche M
Wien Med Wochenschr; 1978; 128(22):697-701. PubMed ID: 83736
[No Abstract] [Full Text] [Related]
32. [Introduction to the International Symposium on Tumor Immunotherapy].
De Barbieri A
Boll Ist Sieroter Milan; 1971; 50(3):137-9. PubMed ID: 5146576
[No Abstract] [Full Text] [Related]
33. Cellular and humoral immune responses of cancer patients to defined tumor antigens.
Jäger D; Jäger E; Bert F; Knuth A
Cancer Chemother Biol Response Modif; 2001; 19():385-93. PubMed ID: 11686025
[No Abstract] [Full Text] [Related]
34. Approaches to immunotherapy.
McKhann CF; Gunnarsson A
Cancer; 1974 Oct; 34(4 Suppl):suppl:1521-31. PubMed ID: 4608719
[No Abstract] [Full Text] [Related]
35. Immunotherapy for cancer: an overview.
Proctor JW; Lewis MG; Mansell PW
Can J Surg; 1976 Jan; 19(1):12-9. PubMed ID: 1145
[TBL] [Abstract][Full Text] [Related]
36. Immunology and the melanomas.
Lewis MG
Curr Top Microbiol Immunol; 1974; 63():49-84. PubMed ID: 4597749
[No Abstract] [Full Text] [Related]
37. [Immunology and immunotherapy of lung cancer--experimental and clinical investigations (author's transl)].
Micksche VM
Wien Klin Wochenschr Suppl; 1978; 90():1-28. PubMed ID: 362733
[No Abstract] [Full Text] [Related]
38. Immunologic aspects of malignancy: Factors of concern in the prospective candidate for immunotherapy.
Ablin RJ
Allergol Immunopathol (Madr); 1975; 3(2):105-8. PubMed ID: 1155313
[No Abstract] [Full Text] [Related]
39. Mechanisms of tumor-induced immunological deficiencies and their possible significance in relation to the use of immunopotentiators in tumor-bearing hosts.
Kerbel RS
Biomedicine; 1974 Jul; 21(7):253-61. PubMed ID: 4547979
[No Abstract] [Full Text] [Related]
40. Immunology of malignancy.
Kaufman JR
J Indiana State Med Assoc; 1975 Aug; 68(8):712-5. PubMed ID: 1095658
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
